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Abstract
Over the past 40 years more than 100 genetic risk factors have
been defined in systemic lupus erythematosus through a
combination of case studies, linkage analyses of multiplex families,
and case-control analyses of single genes. Multiple investigators
have examined patient cohorts gathered from around the world,
and although we doubt that all of the reported associations will be
replicated, we have probably already discovered many of the
genes that are important in lupus pathogenesis, including those
encoding human leukocyte antigen-DR, Fcγ receptor 3A, protein
tyrosine phosphatase nonreceptor 22, cytotoxic T lymphocyte
associated antigen 4, and mannose-binding lectin. In this review
we will present what is known, what is disputed, and what remains
to be discovered in the world of lupus genetics.
Introduction
Systemic lupus erythematosus (SLE) has long been
appreciated to arise from both genetic and environmental
factors. Although environmental factors, such as the Epstein-
Barr virus, are clearly important [1], this review focuses on
genetic factors that are involved in SLE. Evidence for the
genetic origins of the disease come from the observation of
familial aggregation [2] (up to 10% of patients with SLE have
another family member with the disease) and increased
concordance in monozygotic twins [3]. The patterns of
inheritance are complex, however, and it is generally thought
that variations in a number of genes are involved, each
contributing a small amount to the overall genetic risk [4].
Two major strategies have been used to search for the ‘lupus
genes’: genome-wide screening, using multiplex families and
linkage analysis; and candidate gene studies, usually
performed on trios or case-control collections. With either
strategy, a high threshold is necessary to establish genetic
risk, and follow-up testing of an independent cohort is
required to confirm the results.
Genome-wide linkage studies for systemic
lupus erythematosus
The genetic basis of SLE is well established, but the genetic
transmission of SLE has proven to be highly complex.
Consequently, gene identification has been accomplished for
only a handful of genes. Genome-wide linkage scanning is a
comprehensive and unbiased approach to identifying
chromosomal loci that may be linked to complex diseases [5].
Testing for genome-wide linkage is fundamentally a statistical
process that evaluates for co-inheritance of genetic markers
(such as DNA polymorphisms) with the disease phenotype in
families with multiple affected members. Consistent co-
inheritance of the marker with the disease in families means
that they are ‘linked’ and indicates that the actual disease
gene is in close proximity. As with other complex diseases,
genome scans for SLE susceptibility genes suffer from low
power to detect true-positive linkages. Causes of this include
relatively small study populations in some studies and
common causative alleles with low penetrance.
Several different study designs have been used for genome-
wide scanning to identify novel susceptibility loci for SLE.
Some of the study designs involve sibling pairs, for whom
parents may or may not be available. Others use extended
pedigrees with several generations available for study.
Several genome scans have been carried out by four major
scientific groups (located in California, Oklahoma, Minnesota,
and Sweden), and these have identified many loci spread
across the genome. To date, nine independently identified
linkages have been established and replicated in an
independent sample (Table 1). Because each of these
linkages has passed the recommended threshold for
establishing significant evidence of linkage, a susceptibility
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gene or genes is likely to be found eventually within these
linkage regions, although most remain to be identified.
Genes found through linkage studies
The search for genes in the 1q23 linkage interval [6,7] has
led to intensive study of the immunoglobulin receptors
encoded there. There are three distinct but closely related
classes of Fcγ receptors (FCGRs) in humans: FCGR1
(CD64), FCGR2A (CD32), and FCGR3A (CD16). They have
different affinities for IgG and its subclasses, and those
encoded on 1q23 include FCGR2A, FCGR2B, FCGR3A,
and FCGR3B. The arginine variant at amino acid position
131 of FCGR2A (or R131) is associated with SLE,
particularly in African-Americans [8], whereas FCGR3A-F176
is associated with SLE in European derived peoples and
other ethnic groups [7]. A gene dose effect with FCGR2A-
R131 for the risk for SLE was also identified in a meta-
analysis [9], with the risk for SLE increasing with the number
of R alleles (RR > RH > HH). The data that FCGR3A-F176 is
a risk factor for lupus nephritis are also convincing [10].
Because both of these mutations produce receptors with
lowered affinity for IgG [11], it is thought that these variants
may predispose to autoimmunity through delayed clearance
of immune complexes, but this remains an unproven
hypothesis. Although one of these two variants is probably
responsible for the linkage in this region, there are conflicting
data on which is the most important, and this remains an area
of active interest [7,9,10,12].
PDCD1 (programmed cell death 1) is generally accepted as
the gene responsible for the linkage at 2q34 [13], and it is
also associated with lupus nephritis [14]. To date, this is the
only gene to have been identified through fine mapping of a
linkage interval, although this association does not go
unchallenged in other populations tested [15]. The presumed
mechanism of action is through an intronic single nucleotide
polymorphism (SNP) that alters a binding site for the RUNX1
transcription factor, leading to decreased expression of the
PDCD1-encoded protein and delayed apoptosis [13]. Auto-
reactive T cells that fail to undergo apoptosis properly may
persist to support autoimmune responses.
The genes responsible for linkage at the other loci are not so
straightforward. Although it is generally accepted that human
leukocyte antigen (HLA)-DR is associated with SLE [16],
there are a number of other genes in the HLA region that may
also contribute to this linkage, as discussed below. PARP
(poly-[ADP-ribose] polymerase) was initially identified as the
gene responsible for linkage at 1q41 [17], but two
subsequent studies in European-American [18] and French
Caucasian [19] cohorts failed to confirm this association.
Two additional studies conducted in Asian populations also
failed to find an association with disease, although both found
correlation of PARP alleles with clinical manifestations
(discoid rash and anticardiolipin IgM [20], and nephritis and
arthritis [21]).
Linkage analysis through pedigree stratification
Clinical manifestations of SLE are extremely diverse and
variable, both in individual patients and over time. We
hypothesize that genetic factors contribute to this clinical
diversity and that there will be subsets of genes that are over-
Table 1
Confirmed linkage effects in systemic lupus erythematosus
Linkage LOD  Study  Cohort 
region  score center Study design Associated gene(s) Mouse ortholog ethnicity Ref(s)
1q23 4.0 OMRF Extended  pedigrees FCGR2A, FCGR3A sle1, nba2 [54] EA, AA  [6,7]
1q31-32 3.8 UU Extended pedigrees sle1c [84] EU [6,85]
1q41-43 3.3 UCLA Extended pedigrees PARP* EA, HIS  [7,86]
USC
2q37 4.2 UU Extended pedigrees PDCD-1 EU [13,87]
4p16 3.8 OMRF Extended pedigrees sle6 [88] EA [89,90]
6p11-21 4.2 UMN Sib-pairs HLA-DR sles1 [88,91] EA, HIS, AA [16]
10q22-23 P = 0.0002† OMRF Extended pedigrees,  AA [92-94]
UCLA sib-pairs
12q24 3.3 OMRF Extended pedigrees HIS, EA  [95]
16q12-13 3.4 UMN Sib-pairs,  EA, AA, HIS  [96,97]
OMRF extended pedigrees
*Although there was initial evidence that PARP was the gene responsible for this linkage [17], subsequent studies have failed to confirm an
association [18-21]. †The initial linkage at 10q22 was described using allele sharing statistics; therefore, a P value is generated instead of a log of
odds (LOD) score. AA, African-Americanl EA, European-American; EU, European; HIS, Hispanic; OMRF, Oklahoma Medical Research Foundation;
UCLA, University of California at Los Angeles; USC, University of Southern California; UU, Uppsala University (Sweden).Page 3 of 9
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represented in families with particular clinical manifestations.
We therefore used stratification of multiplex pedigrees by
phenotype to improve the genetic homogeneity of our cohorts
and discover new loci linked to SLE. For example, by analyzing
only the families in which one or more members have vitiligo,
we identified linkage at 17p12 [22] and six additional linked
loci were discovered through stratification by other clinical and
laboratory criteria. All of these have been established and
confirmed in an independent cohort (Table 2).
Genome scan meta-analysis
Although several susceptibility loci for SLE have been
identified by individual genome-wide scans, many of these
loci have yielded inconsistent results across studies.
Additionally, many individual studies are at the lower limit of
acceptable power recommended for declaring significant
linkage. The genome search meta-analysis has been
proposed as a valid and robust method for combining several
genome scan results [23]. Recently, the results of two
genome search meta-analyses were reported [24,25]. These
studies identified many linked regions that may harbor the
SLE susceptibility genes. The most interesting results
emerging from these studies are significant linkages in the
intervals of 6p21-6p22 and 16p12-16q13.
Overview of candidate gene studies
The candidate gene approach is the technique most
frequently used to explore SLE genetics. It is simple and
straightforward, namely recruit lupus patients and matched
controls, assay them for variations in a gene of interest, and
determine whether allele frequencies differ between the two
groups. Because of the relative ease of the approach, there
are literally hundreds of association studies in SLE (for
review, see [26]). If they were all the same, then comparing
them and correlating the results would be a simple matter,
but science is, of course, performed by individuals, each with
their own ideas. This has lead to variations in nearly every
aspect of methodology, from the way in which patients were
recruited and matched to the number of SNPs assayed in
each gene. The ethnic groups studied are as varied as the
international sites at which this work was accomplished, and
of course everyone has different ideas about what genes are
‘of interest’.
Currently, 115 different genetic loci have been reported to be
in association with SLE, but there are conflicting reports that
claim no association for 56 of these. Of course, many of
these ‘conflicting’ reports were conducted in patients from
different ethnic groups, and so both reports may be correct
and merely indicate ethnic specificity for a gene. There are
also 71 genes for which only a single study has been
published to date. Within these 39 positive and 32 negative
analyses, there exist both strong associations in large cohorts
(which are generally more reliable) and weak associations in
small, isolated populations. It therefore remains to be seen
which of these unconfirmed associations will prove to be
consistent in future studies. Sample size, ethnicity, and
number of SNPs studied should be considered when reading
a single report on the role of any given gene in SLE, and one
must keep in mind that the literature in this area is vast and
multiple studies often exist. It is currently believed that on the
order of 20 to 40 genes have variants that play a role in SLE
risk. Therefore, although the majority of the genetic risk
factors for SLE may be on this list of 115, we do not yet know
which ones are really important. Nevertheless, out of this
body of work in progress, several strong associations rise to
the top. These include components of the C3b activation
pathway, the FCGRs, HLA region genes, and a number of
genes that have been implicated in immune regulation, as
listed in Table 3.
Specific genes associated with systemic
lupus erythematosus
Complement deficiencies
There are a few instances in which mutation of a single gene
causes lupus or a lupus-like syndrome. The most common of
Available online http://arthritis-research.com/content/9/3/210
Table 2
Linkage effects found in OMRF pedigrees using stratification
Linkage region  LOD Cohort ethnicity Stratification criteria Ref(s)
2q34* P = 0.00002† AA Nephritis [93,94]
5p15 6.2 EA, AA, HIS Alleged rheumatoid arthritis [98,99]
5q14 5.0 EA Autoimmune thyroid disease [100]
11p13 3.7 AA  Discoid lupus, thrombocytopenia [101,102]
11q14 4.7 AA  Hemolytic anemia, nucleolar ANA [102-104]
17p12 4.0 EA Vitiligo [22,105]
19p13.2 3.6 EA Anti-dsDNA [87,106]
*This region is orthologous to that containing the mouse lupus susceptibility locus sle7 [107]. †The 2q34 region was analyzed using sib-pair
methods; therefore, a P value is generated instead of a log of odds (LOD) score. AA, African-American; ANA, anti-nuclear antibody; EA, European-
American; HIS, Hispanic; OMRF, Oklahoma Medical Research Foundation.these is a deficiency of complement component C2 [27],
which occurs in 1/10,000 individuals [28], and nearly one-
third of these patients will develop SLE [29]. Although the
gene encoding C2 is in the same region as the major
histocompatibility complex (MHC), two studies [30,31] have
concluded that MHC genes are not responsible for the
phenotype in C2-deficient patients. The mild phenotype and
female predominance in C2-deficient SLE patients may be
due to other genetic influences that remain to be determined.
Most individuals carry four copies of the C4 gene cassette,
which lies within the MHC cluster, but copy numbers can vary
between 0 and 6 [32]. Minor variations within the cassette
provide the designations C4A and C4B, and the majority of
individuals carry two copies of each, although there is
considerable variation in the population. Complete deficiency
of all copies of the C4 cassette has been shown to cause
severe SLE as well as susceptibility to infection, but this
condition is quite rare [33]. A partial deficiency, usually with
deletion of a single C4A allele (also known as C4A*Q0 or C4
null), has been associated with disease risk; however,
C4A*Q0 is in linkage disequilibrium with DR3 [34], an MHC
haplotype that is strongly associated with autoantibody
production and SLE in its own right [4]. Rare deficiencies in
C1q, C1r, and C1s also appear to cause SLE [27].
It would appear to be no coincidence that C2, C4, and C1
are all components of the classical pathway, through which
immune complexes activate complement. Genetic defects in
C3 or in any of the terminal complement components (C5 to
C9) generally result in increased sensitivity to infection,
particularly from Gram-negative bacteria such as Neisseria
meningitidis [27]. The early complement components are
important for keeping immune complexes in soluble form, as
well as for clearance of apoptotic bodies [35]. Additionally,
C4 is critical for maintenance of B-cell tolerance [36], which
may prove to be even more important than delayed immune
complex clearance in the pathogenesis of SLE in these
patients.
Human leukocyte antigen region
After considering these single genes, perhaps the next
clearest genetic effect in SLE is in the HLA region. Although
multiple studies conducted during the past 40 years have
shown clear HLA associations [4,26,37], it is currently
uncertain which gene or genes may be responsible for
increasing genetic risk. This region contains not only the HLA
class I, II and III genes, but also the genes that encode
complement components C2 and C4, tumor necrosis factor
(TNF)-α and TNF-β (also known as lymphotoxin-α LTA),
transporter associated with antigen processing (TAP)1 and
TAP2, butyrophilin-like protein 2, and numerous heat-shock
protein genes and others with possible immune significance.
Furthermore, these genes are often inherited as a block, a
phenomenon known as linkage disequilibrium, so that - for
example - the TNF-α -308A variant associated with over-
expression is often found in a haplotype block that also
contains HLA-B8, C4A null, and HLA-DR3 [38]. It is
unfortunate that most of the studies in this region focus on a
single marker, most often either HLA-DR or TNF-α, either of
which could be responsible for this extended haplotype. To
add additional confusion to the issue of pathogenicity, more
than one HLA allele has been found to associate with
disease, for example DR3 and DR2, and these associations
are not necessarily confined to a single ethnic group [37].
Arthritis Research & Therapy    Vol 9 No 3 Sestak et al.
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Table 3
Genes associated with systemic lupus erythematosus
Gene name Locus ID Location Evidence
C1Q 712 1p36 Causative mutations found [27,35]
C2 717 6p21 Causative mutations found [28,29]
C4 721 6p21 Causative mutations found [33,35]
PTPN22 26,191 1p13 Meta-analysis [47]
FCGR2A 2,212 1q23 Meta-analysis [9,12] 
FCGR3A 2,214 1q23 Meta-analysis [10,12]
IL10 3,586 1q32 Meta-analysis [43]
CTLA4 1,493 2q33 Meta-analysis [45]
HLA-DRB1 3,123 6p21 Multiple positive reports [4,26,37] 
TNFα 7,124 6p21 Meta-analysis [46]
TNFβ 4,049 6p21 Multiple positive reports [26]
MBL 4,153 10q11 Meta-analysis [44]It is reasonable to think that any of these variants could
contribute to the lupus phenotype. As discussed above,
complete deficit of C2 or C4 appears to cause SLE, and
more subtle alterations in the classical pathway may also
cause some tendency toward autoimmunity. The HLA
proteins are directly involved in antigen presentation, and in
some cases, such as in HLA-B27 arthritis, this has been
shown to lead to alteration in the immune repertoire [39].
TNF-α is central to regulation of many inflammatory pathways,
and treatment with TNF-α inhibitors can cause lupus flares or
lupus-like symptoms, possibly through upregulation of IFN-α
[40], indicating a complex role for this cytokine in SLE. TNF-β
is key to the formation of normal lymph nodes [41], and the
gene encoding TNF-β is one of the most consistently
associated across populations, with seven positive reports
and no negative reports to date [26]. TAP1 and TAP2 are
involved in peptide processing for antigen presentation, and
transgenic mice that lack TAP are resistant to experimentally
induced SLE [42]. It is possible that any one of these defects
alone could predispose to SLE, but it is also possible that it
takes some combination of ‘hits’ to produce an extended
haplotype that correlates more directly with disease risk.
Meta-analysis of candidate genes in systemic lupus
erythematosus
When there are several studies on the same allele in a gene,
meta-analysis can be a useful tool for sorting out any
conflicting reports, but usually there are not enough studies
performed to make this practical. For some of the more
extensively studied genes, however, it represents a powerful
tool. For example, the majority of the reports on the gene
encoding interleukin-10 support association, as does a
recent meta-analysis [43], although there is a body of
literature that supports only associations with specific
phenotypes as well as half a dozen negative reports. Meta-
analysis also favors association with the mannose-binding
lectin (MBL) gene, although the individual reports are evenly
divided in favor and in opposition [44]. The situation is similar
with cytotoxic T lymphocyte associated antigen (CTLA)4, in
which association is also favored even though the literature is
mixed, with the strongest effects seen in Asian populations
[45]. TNF-α also has mixed reports but a positive meta-
analysis, particularly in European-Americans [46]; interpre-
tation of this finding is problematic, however, because TNF-α
is in linkage disequilibrium with HLA-DR [38]. The cumulative
data support an association of the protein tyrosine phos-
phatase nonreceptor (PTPN)22 gene with SLE as well [47].
Meta-analyses are not always positive, however; meta-
analysis of the data on the widely studied insertion/deletion
polymorphism in the angiotensin-converting enzyme gene
does not favor association with SLE or lupus nephritis [48].
Single gene defects reflected in mouse models of lupus
A number of murine models of lupus have been charac-
terized, and they include both transgenic constructs and
strains with naturally occurring disease (for review, see
[49-56]). Some of these animal models have led us to
discover single gene deficiencies that are found rarely in
human disease, as well as a number of candidate genes for
association. MRL/lpr mice, a murine model of lupus, are
deficient in Fas [57], and deficiencies of Fas in humans cause
autoimmune lymphoproliferative syndrome [58]. DNAse1-
deficient mice also serve as a model of lupus [59], and there
are reports of DNAse1 deficiency leading to SLE in human
families [60,61]. Although these examples suggest a general
effect, the literature contains roughly equal numbers of
reports for and against the association of Fas, Fas ligand, and
DNAse1 with SLE in larger case-control studies [26]. It is
therefore difficult to draw any firm conclusions about the role
of these genes in SLE pathogenesis in the general
population. Other interesting mouse knockout models that
develop autoimmune phenotypes include those for C1Q [62],
Fcγ [63], and Toll-like receptor-7 [64]. Mapping of the genes
responsible for disease in spontaneous models of lupus in
mice is another area of active interest, and the overlap
between the search for autoimmune genes in human and
mouse is due to expand and integrate rapidly as new
technologies are brought to bear on this area [51].
Interferon-related candidate genes
Genes in the IFN family have also been implicated in SLE.
The well known IFN signature [65] has provided the
inspiration for a number of candidate gene studies. Initial
associations with IFN-γ [66] and the IFN receptors [67] have
not been confirmed in additional cohorts [68-70]. Most
recently, however, a study conducted in a large Nordic cohort
[71] demonstrated an association with the IFN-regulatory
factor (IRF)5 gene; and this has sparked a flurry of strong
confirmation and characterization reports [72-74]. These four
studies all confirm the association of IRF5 with SLE, which
appears to be quite robust, although the genetics in this
region are complex and several variations appear to combine
to form the risk haplotypes [74]. Additional work character-
izing the IRF5 alleles associated with SLE is in progress.
Epigenetic work
Epigenetics refers to the inherited chromatin changes that
alter gene expression without affecting DNA sequence.
Although there is a clear evidence that genetic factors
contribute to the pathogenesis of lupus, as detailed above,
epigenetic abnormalities have also been implicated in this
disease. Over the past 20 years, a series of reports
documented a role for abnormal DNA methylation in the
pathogenesis of both drug-induced and idiopathic lupus [75].
DNA methylation is an epigenetic mechanism, which refers to
adding a methyl group, donated by S-adenosylmethionine, to
the fifth carbon on cytosine residues within CpG dinucleotide
pairs. CpG pairs located within CpG islands are present in
promoter sequences of about 40% to 50% of mammalian
genes [75]. In general, methylated CpG pairs suppress gene
expression whereas hypomethylated CpG pairs are associa-
ted with transcriptional activity [76].
Available online http://arthritis-research.com/content/9/3/210
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sing unnecessary genes during tissue differentiation, inhibit-
ing the expression of parasitic DNA, genomic imprinting, and
female X chromosome inactivation. De novo DNA methylation
takes place early on in fetal life and during differentiation, and is
mediated by DNA methyltransferase (DNMT)3a and DNMT3b
enzymes, which are capable of methylating previously
unmethylated DNA. The pattern of DNA methylation is then
maintained during cell division by the enzyme DNMT1 [77].
Global hypomethylation in T cell DNA has been described in
lupus [78]. Indeed, this was subsequently found to result
from reduced expression of DNMT1 in lupus T cells [79].
Lupus-inducing drugs such as procainamide and hydralazine
result in T cell hypomethylation in vitro [80], similar to T cells
from active lupus patients. Although procainamide is a
competitive inhibitor of DNMT1, hydralazine reduces DNMT1
expression by inhibiting signaling through the extracellular
signal-regulated kinase (ERK) signaling pathway, which, at
least in part, regulates DNMT1 expression in T cells [81].
T cells treated with DNA methylation inhibitors or ERK
pathway signaling inhibitors become autoreactive in vitro and
cause autoimmunity, manifested as lupus-like disease, when
injected into syngeneic mice [75]. For example, D10 mouse
T cells treated with 5-azacytidine and adoptively transferred
into syngeneic female AKR mice resulted in anti-dsDNA anti-
bodies, anti-histone antibodies, immune complex glomerulo-
nephritis, alveolitis, and meningitis [82]. Hypomethylation in
lupus T cells is thought to contribute to the increased
expression of several methylation sensitive genes, including
ITGAL (CD11a), PRF1 (perforin), and TNFSF7 (CD70) [83].
The expression of these genes is increased in lupus T cells,
T cells treated with the DNA methylation inhibitor 5-aza-
cytidine, as well as T cells treated with the lupus inducing
drugs procainamide and hydralazine [75]. Promoter sequence
hypomethylation of these genes has been demonstrated in
T cells from lupus, and the pattern of hypomethylation is
similar to that observed in T cells from normal donors that are
treated with DNA methylation inhibitors in vitro [75].
Conclusion
Many of the important genetic risk factors for SLE have been
discovered through linkage and association studies, and the
body of work in this area is impressive. Nine linkage regions
have been established and confirmed for SLE, and an
additional seven linkage regions have been established and
confirmed using stratification by clinical and laboratory
criteria. Two high-throughput platforms for SNP typing have
been developed in recent years: AffyMetrix GeneChip®
Mapping Arrays (AffyMetrix, Inc., Santa Clara, CA, USA),
which type up to 500,000 SNPs at a time; and the Illumina
HumanHap300-Duo bead chip system (Illumina, Inc., San
Diego, CA, USA), which covers 318,000 markers largely
derived from the Phase I HapMap set. Both companies plan
the release of improved technology within the year, with
AffyMetrix releasing a new gene chip system covering over a
million SNPs and Illumina releasing a new bead chip with
expanded coverage of Phase II HapMap SNPs and improved
MHC coverage. The first major whole-genome scan using
high-throughput SNP technology is now in progress, and we
expect it to confirm many of the known effects as well as
allow discovery of new gene associations. The major effects
confirmed through more traditional single gene studies
include complement components C2, C4, and C1q, the HLA
region, the FCGR2A and FCGR3A, PDCD1, CTLA4,
interleukin-10, MBL, and PTPN22. There are nearly 100 other
genes that have been reported to be associated with SLE,
the majority of which are either disputed or unconfirmed at
this time. Much additional work remains to be done in this
area. The ways in which these genes might interact also
remains to be explored, and combinations of susceptibility
factors may prove to be powerfully predictive. Epigenetic
factors such as DNA hypomethylation are also likely to play a
role in lupus pathogenesis.
The future of lupus genetics is exciting and complicated. As
the major research projects currently underway come to
fruition, we will see the largest cohort to date undergo a high-
density association genome scan. These data will be corre-
lated with both clinical information and with gene expression
data. Although data analysis will be complicated and ripe with
false-positive effects, the end result should be the clearest
picture of the cascade from risk allele to immune pathology
that we have been able to generate to date. These models
will not be nearly as biased by prior information, because
both the allele association and gene expression data will be
gathered globally, without focusing on what ‘should be’
downstream of each effect. With such a large dataset to
explore, gene interaction effects should become clearer and
unanticipated relationships will probably emerge. Candidate
gene discovery from murine lupus models is also reaching a
threshold, and the cross-talk between human and murine
studies will continue to fuel productive research. As new data
are gathered and analyzed, we should be able to sort through
the false-positive effects more easily and understand the
interactions of the true-positive effects. This will enable us to
build a more cohesive picture of the genetic risk factors that
are involved in the development of SLE and give direction for
new and innovative therapeutic options.
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